CLINICAL TRIALS PROFILE FOR MUPIROCIN
✉ Email this page to a colleague
All Clinical Trials for MUPIROCIN
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00108160 ↗ | Preventing Staphylococcal (Staph) Infection | Completed | Saint Joseph Mercy Health System | Phase 4 | 2005-04-01 | The purpose of this study is to determine if mupirocin 2% in polyethylene glycol (PEG) ointment [Treatment Arm] is effective in preventing moderate to severe re-infection with Staphylococcus aureus compared with treatment with polyethylene glycol (PEG) ointment [Placebo Arm]. |
| NCT00108160 ↗ | Preventing Staphylococcal (Staph) Infection | Completed | University of Michigan | Phase 4 | 2005-04-01 | The purpose of this study is to determine if mupirocin 2% in polyethylene glycol (PEG) ointment [Treatment Arm] is effective in preventing moderate to severe re-infection with Staphylococcus aureus compared with treatment with polyethylene glycol (PEG) ointment [Placebo Arm]. |
| NCT00108160 ↗ | Preventing Staphylococcal (Staph) Infection | Completed | US Department of Veterans Affairs | Phase 4 | 2005-04-01 | The purpose of this study is to determine if mupirocin 2% in polyethylene glycol (PEG) ointment [Treatment Arm] is effective in preventing moderate to severe re-infection with Staphylococcus aureus compared with treatment with polyethylene glycol (PEG) ointment [Placebo Arm]. |
| NCT00108160 ↗ | Preventing Staphylococcal (Staph) Infection | Completed | VA Office of Research and Development | Phase 4 | 2005-04-01 | The purpose of this study is to determine if mupirocin 2% in polyethylene glycol (PEG) ointment [Treatment Arm] is effective in preventing moderate to severe re-infection with Staphylococcus aureus compared with treatment with polyethylene glycol (PEG) ointment [Placebo Arm]. |
| NCT00156377 ↗ | Prophylaxis With Intranasal Mupirocin for Prevention of S. Aureus Infections | Completed | GlaxoSmithKline | Phase 4 | 2002-11-01 | In order to evaluate the effect of eliminating nasal carriage by mupirocin prophylaxis on subsequent Staphylococcus aureus infection, a prospective randomized trial was performed particularly including patients with predisposing risk factors for S. aureus infections. |
| NCT00156377 ↗ | Prophylaxis With Intranasal Mupirocin for Prevention of S. Aureus Infections | Completed | University Hospital Muenster | Phase 4 | 2002-11-01 | In order to evaluate the effect of eliminating nasal carriage by mupirocin prophylaxis on subsequent Staphylococcus aureus infection, a prospective randomized trial was performed particularly including patients with predisposing risk factors for S. aureus infections. |
| NCT00179959 ↗ | The Impact of Treating Staphylococcus Aureus Infection and Colonization on the Clinical Severity of Atopic Dermatitis | Completed | Johnson & Johnson | Phase 4 | 2005-09-01 | Staphylococcus aureus (S. aureus) infection is perceived not only as a common secondary complication of atopic dermatitis (AD), but also as a culprit in the worsening of this condition. In addition, the recent development of community acquired methicillin-resistant S. aureus (CA-MRSA) has presented a new challenge to our management of AD, both in treatment of acute infections and maintenance therapy. The investigators would like to perform a randomized investigator-blinded placebo-controlled study of children aged 6 months to 17 years with moderate to severe atopic dermatitis with clinical signs of secondary bacterial infection to study: 1) the prevalence of CA-MRSA in our patient population; 2) the relationship of sensitivity of the S. aureus organism cultured from the infected lesion(s) to clinical response to oral cephalexin therapy and severity of the AD; and 3) whether concurrent treatment of S. aureus infection initially with nasal mupirocin ointment and sodium hypochlorite (bleach) baths can result in long-term S. aureus eradication and clinical stability. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for MUPIROCIN
Condition Name
Clinical Trial Locations for MUPIROCIN
Trials by Country
Clinical Trial Progress for MUPIROCIN
Clinical Trial Phase
Clinical Trial Sponsors for MUPIROCIN
Sponsor Name
